Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
下载
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [21] Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients
    Bertelli, G
    Queirolo, P
    Vecchio, S
    Angiolini, C
    Bergaglio, M
    Del Mastro, L
    Signorini, A
    Valenzano, M
    Venturini, M
    ANTICANCER RESEARCH, 2000, 20 (5C) : 3659 - 3661
  • [22] TAMOXIFEN AS ADJUVANT THERAPY IN BREAST-CANCER PATIENTS
    NICOLINI, A
    TOSCANO, S
    GIULIANI, L
    DIMARCO, G
    CARPI, A
    ANTICANCER RESEARCH, 1986, 6 (03) : 397 - 397
  • [23] Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment Balance of Breast Risks and Endometrial Benefits-Systematic Review of Literature
    Gizzo, Salvatore
    Di Gangi, Stefania
    Bertocco, Anna
    Noventa, Marco
    Fagherazzi, Simone
    Ancona, Emanuele
    Saccardi, Carlo
    Patrelli, Tito Silvio
    D'Antona, Donato
    Nardelli, Giovanni Battista
    REPRODUCTIVE SCIENCES, 2014, 21 (04) : 423 - 431
  • [24] Balancing the Risks and Benefits of Extended Adjuvant Endocrine Therapy
    Jhaveri, Komal L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 105 - 108
  • [25] Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer (vol 91, pg 1829, 1999)
    Gail
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (03): : 275 - 275
  • [26] Adjuvant tamoxifen-treatment in breast cancer patients. Effects on coagulation and fibrinolysis
    Oberhoff, C
    Hoffmann, O
    Szymeczek, J
    Winkler, UH
    Schindler, AE
    10TH INTERNATIONAL MEETING OF GYNAECOLOGICAL ONCOLOGY, 1997, : 411 - 414
  • [27] Retrospective analysis of hysteroscopic findings in breast cancer patients having adjuvant tamoxifen treatment
    Sendag, F.
    Sahin, C.
    Zeybek, B.
    Terek, M. Cosan
    Oztekin, K.
    Bilgin, O.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (04) : 415 - 417
  • [28] Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
    Hadji, P.
    Ziller, V
    Holzhauer, W.
    Ziller, M.
    Kalder, M.
    Wagner, U.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S146 - S146
  • [29] UTERINE CARCINOSARCOMA AFTER ADJUVANT TAMOXIFEN TREATMENT FOR BREAST CANCER
    Wuntakal, R.
    Lane, G.
    Menon, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1406 - 1406
  • [30] TAMOXIFEN (TMX) AS ADJUVANT TREATMENT OF BREAST-CANCER - AN APPRAISAL
    BOCCARDO, F
    ANTICANCER RESEARCH, 1986, 6 (03) : 355 - 356